5-{2-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]ethoxy}-2,3-dihydro-1H-inden-1-yl acetic acid | 496061-92-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-{2-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]ethoxy}-2,3-dihydro-1H-inden-1-yl acetic acid
• 英文别名: 2-((1S)-5-{2-[5-methyl-2-(4-methylphenyl)(1,3-oxazol-4-yl)]ethoxy}indanyl)acetic acid；2-[5-[2-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]ethoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid
• CAS: 496061-92-8
• 化学式: C₂₄H₂₅NO₄
• 分子量: 391.467
• InChiKey: CNNWFMRXRJIMNL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  72.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  ethyl 2-((1S)-5-{2-[5-methyl-2-(4-methylphenyl)(1,3-oxazol-4-yl)]ethoxy}indanyl)acetate 、 aqueous LiOH 生成 5-{2-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]ethoxy}-2,3-dihydro-1H-inden-1-yl acetic acid
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
  申请人：——

  公开号：US20030216391A1

  公开（公告）日：2003-11-20

  This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.

  这项发明涉及新颖的茚基乙酸衍生物，可用于治疗糖尿病、肥胖症、高脂血症和动脉粥样硬化等疾病。该发明还涉及用于制备茚基乙酸衍生物的中间体以及制备方法。
• [EN] METHODS OF TREATING LIVER DISEASE USING INDANE ACETIC ACID DERIVATIVES<br/>[FR] PROCÉDÉS DE TRAITEMENT D'UNE MALADIE HÉPATIQUE AU MOYEN DE DÉRIVÉS D'ACIDE INDANE-ACÉTIQUE
  申请人：T3D THERAPEUTICS INC

  公开号：WO2016154258A1

  公开（公告）日：2016-09-29

  This invention describes the use of indane acetic acid derivatives which are dual PPAR delta / gamma agonists for the treatment of liver diseases including one or more of the following: NAFLD (Non Alcoholic Fatty Liver Disease), NASH (Non Alcoholic Steatohepatitis), Farber's Disease, ACLF (Acute-on-Chronic Liver Failure), CLF (Chronic Liver Failure), POLT-HCV-SVR (Post-Orthotopic Liver Transplant due to Hepatitis C Virus infection after Sustained Viral Response following anti-HCV therapy), Alagille syndrome, PFIC (Progressive Familial Intrahepatic Cholestasis), PBC (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, ADPCLD (Autosomal Dominant Polycystic Liver Disease), Treatment of liver transplant patients with reestablished fibrosis, CESD (Cholesteryl Ester Storage Disease), SHTG (Severe Hypertriglyceridemia), HoFH (Homozygous Familial Hypercholesterolemia), HE (Hepatic Encephalopathy), or Alcoholic Liver Disease.

  本发明描述了使用具有双重 PPAR delta / gamma 激动剂作用的茚烷乙酸衍生物治疗肝病，包括以下一种或多种疾病：非酒精性脂肪肝病（NAFLD）、非酒精性脂肪性肝炎（NASH）、法伯氏病、急性慢性肝衰竭（ACLF）、慢性肝衰竭（CLF）、因抗 HCV 治疗后持续病毒学应答而进行的肝移植术后的 HCV 感染（POLT-HCV-SVR）、艾拉吉尔综合征、渐进性家族性肝内胆汁淤积症（PFIC）、原发性胆汁性肝硬化（PBC）、原发性硬化性胆管炎、常染色体显性多囊性肝病（ADPCLD）、重新建立纤维化的肝移植患者的治疗、胆固醇酯贮积病（CESD）、严重高甘油三酯血症（SHTG）、纯合子家族性高胆固醇血症（HoFH）、肝性脑病（HE）或酗酒性肝病。
• [EN] INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION<br/>[FR] DERIVES D'ACIDE ACETIQUE D'INDANE ET LEUR UTILISATION EN TANT QU'AGENTS THERAPEUTIQUES, PRODUITS INTERMEDIAIRES, ET LEUR METHODE DE PREPARATION
  申请人：BAYER AG

  公开号：WO2003011842A1

  公开（公告）日：2003-02-13

  This invention relates to novel indane acetic acid derivatives of formula (I) which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates of formula (II) a nd (III) of indane acetic derivatives and to methods of prepa ration.

  本发明涉及一种新型吲哚乙酸衍生物的化合物，其化学式为(I)，可用于治疗糖尿病、肥胖症、高脂血症和动脉粥样硬化等疾病。本发明还涉及吲哚乙酸衍生物的中间体化合物，其化学式为(II)和(III)，以及制备方法。
• INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION
  申请人：Bayer Corporation

  公开号：EP1414809A1

  公开（公告）日：2004-05-06
• METHODS OF TREATING LIVER DISEASE USING INDANE ACETIC ACID DERIVATIVES
  申请人：T3D Therapeutics Inc.

  公开号：EP3273964A1

  公开（公告）日：2018-01-31